A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 92,900 shares of BEAM stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,900
Previous 81,900 13.43%
Holding current value
$2.28 Million
Previous $1.92 Million 18.67%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $16.4 Million - $24.1 Million
727,041 Added 94.52%
1,496,195 $36.7 Million
Q2 2024

Aug 14, 2024

BUY
$21.22 - $32.66 $15.5 Million - $23.8 Million
729,641 Added 1846.58%
769,154 $18 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $658,475 - $1.27 Million
28,068 Added 245.24%
39,513 $1.31 Million
Q4 2023

Feb 14, 2024

SELL
$17.69 - $30.76 $20.6 Million - $35.8 Million
-1,165,470 Reduced 99.03%
11,445 $311,000
Q3 2023

Nov 14, 2023

BUY
$23.01 - $32.46 $19.7 Million - $27.8 Million
857,371 Added 268.31%
1,176,915 $28.3 Million
Q2 2023

Aug 14, 2023

BUY
$29.32 - $35.99 $4.06 Million - $4.98 Million
138,344 Added 76.35%
319,544 $10.2 Million
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $1.57 Million - $2.53 Million
51,938 Added 40.18%
181,200 $5.55 Million
Q4 2022

Feb 14, 2023

BUY
$36.73 - $51.6 $1.28 Million - $1.8 Million
34,930 Added 37.03%
129,262 $5.06 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $1.63 Million - $2.88 Million
41,000 Added 76.88%
94,332 $4.49 Million
Q2 2022

Aug 15, 2022

SELL
$29.86 - $62.36 $3.32 Million - $6.93 Million
-111,186 Reduced 67.58%
53,332 $2.06 Million
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $4.5 Million - $6.88 Million
83,789 Added 103.79%
164,518 $9.43 Million
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $9.21 Million - $13.4 Million
-135,463 Reduced 62.66%
80,729 $6.43 Million
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $16.4 Million - $26 Million
194,580 Added 900.33%
216,192 $18.8 Million
Q2 2021

Aug 16, 2021

SELL
$64.12 - $128.71 $8.7 Million - $17.5 Million
-135,705 Reduced 86.26%
21,612 $2.78 Million
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $10.5 Million - $17.8 Million
147,684 Added 1533.1%
157,317 $12.6 Million
Q4 2020

Feb 16, 2021

BUY
$22.24 - $95.63 $214,237 - $921,203
9,633 New
9,633 $786,000
Q3 2020

Nov 16, 2020

SELL
$19.0 - $30.57 $515,394 - $829,241
-27,126 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$15.26 - $28.66 $902,979 - $1.7 Million
-59,173 Reduced 68.57%
27,126 $759,000
Q1 2020

May 15, 2020

BUY
$13.31 - $29.2 $1.15 Million - $2.52 Million
86,299 New
86,299 $1.55 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.72B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.